other material
confidence high
sentiment neutral
materiality 0.60
60 Degrees Pharmaceuticals shareholders approve reverse stock split, equity plan amendment, and management success fee
60 DEGREES PHARMACEUTICALS, INC.
- Reverse stock split approved at ratio of 1:5 to 1:10, as determined by board.
- Equity plan amended to increase shares available by 800,000.
- Success fee approved: 5% of deal proceeds between $40M-$100M, 6% above $100M, for change of control or sale of Arakoda.
- Five directors elected: Geoffrey Dow, Eric Francois, Cheryl Xu, Stephen Toovey, Paul Field.
- Ratification of RBSM LLP as independent auditor for FY 2026 approved.